Targeting multidrug resistance in cancer

G. Szakács, Jill K. Paterson, Joseph A. Ludwig, Catherine Booth-Genthe, Michael M. Gottesman

Research output: Contribution to journalArticle

2343 Citations (Scopus)

Abstract

Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.

Original languageEnglish
Pages (from-to)219-234
Number of pages16
JournalNature Reviews Drug Discovery
Volume5
Issue number3
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Multiple Drug Resistance
ATP-Binding Cassette Transporters
Pharmaceutical Preparations
Neoplasms
Poisons
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006). Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery, 5(3), 219-234. https://doi.org/10.1038/nrd1984

Targeting multidrug resistance in cancer. / Szakács, G.; Paterson, Jill K.; Ludwig, Joseph A.; Booth-Genthe, Catherine; Gottesman, Michael M.

In: Nature Reviews Drug Discovery, Vol. 5, No. 3, 03.2006, p. 219-234.

Research output: Contribution to journalArticle

Szakács, G, Paterson, JK, Ludwig, JA, Booth-Genthe, C & Gottesman, MM 2006, 'Targeting multidrug resistance in cancer', Nature Reviews Drug Discovery, vol. 5, no. 3, pp. 219-234. https://doi.org/10.1038/nrd1984
Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery. 2006 Mar;5(3):219-234. https://doi.org/10.1038/nrd1984
Szakács, G. ; Paterson, Jill K. ; Ludwig, Joseph A. ; Booth-Genthe, Catherine ; Gottesman, Michael M. / Targeting multidrug resistance in cancer. In: Nature Reviews Drug Discovery. 2006 ; Vol. 5, No. 3. pp. 219-234.
@article{50fe665c2d104c61b084d416bab014e9,
title = "Targeting multidrug resistance in cancer",
abstract = "Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.",
author = "G. Szak{\'a}cs and Paterson, {Jill K.} and Ludwig, {Joseph A.} and Catherine Booth-Genthe and Gottesman, {Michael M.}",
year = "2006",
month = "3",
doi = "10.1038/nrd1984",
language = "English",
volume = "5",
pages = "219--234",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Targeting multidrug resistance in cancer

AU - Szakács, G.

AU - Paterson, Jill K.

AU - Ludwig, Joseph A.

AU - Booth-Genthe, Catherine

AU - Gottesman, Michael M.

PY - 2006/3

Y1 - 2006/3

N2 - Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.

AB - Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.

UR - http://www.scopus.com/inward/record.url?scp=33644775686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644775686&partnerID=8YFLogxK

U2 - 10.1038/nrd1984

DO - 10.1038/nrd1984

M3 - Article

C2 - 16518375

AN - SCOPUS:33644775686

VL - 5

SP - 219

EP - 234

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 3

ER -